How to Trade This Oversold Biopharma Name
A covered call trade idea after a rocky week for the market.
You've reached your free article limit
You've read 0 of 1 free Pro articles.

It was a memorable week, to substantially understate things.Â
The market had its worst weekly performance since the tariff tantrum in April 2025. NVIDIA Corporation (NVDA) continued to sell off despite posting better than expected Q3 results and boosting guidance. The shares are now down over 40% from recent highs, eviscerating over $2 trillion in market cap over the past month and a half. And Anthropic’s (ANT) massive IPO fizzled soon after it began trading on Thursday. In retrospect, this week might turn out to be the week the AI bubble officially burst.
My portfolio fell just a fraction of that of the major indexes this week. Just over 60% of my holdings are in covered call positions in mostly non-AI related stocks with reasonable valuations. The rest is held in short-term treasuries and cash. Holdings that were bolstered a bit by some additional covered call positions expiring in the money at market close Friday. I did put a slug of my cash to work this week, initiating a few new covered call holdings.
And one of these will be the topic of this column and this weekend’s covered call trade idea.Â
It is in a commercial-staged biopharma company called Precigen, Inc. (PGEN). If the name sounds familiar, it might be because this small concern has been extolled several times this year by fellow TheStreet Pro contributor James “RevShark” DePorre. The stock currently trades around $4.25 a share and sports an approximate market cap of $1.5 billion.
The stock has been roughly cut in half this quarter. The selloff was triggered primarily by the FDA approval for VOCERYQ from Inovio Pharmaceuticals (INO). This therapy became the second approved treatment for recurrent respiratory papillomatosis or RRP at the end of October. The first approved treatment for RRP was Precigen’s primary asset PAPZIMEOS, which garnered its FDA approval in the summer of 2025. RRP is a rare condition primarily triggered by HPV that results in wart like growths that can result in airway obstruction.
Precigen posted Q3 numbers earlier this month. Sales of PAPZIMEOS rose 37% sequentially from Q2 and came in just under $73 million. The company became operationally cash flow positive ($11.9 million in Q3) one quarter before previous guidance. PAPZIMEOs has achieved first-mover advantage and received full FDA approval without the need for a confirmatory trial. It already has achieved broad payer coverage and the coveted J-code. Management continues to project it will get to blockbuster status, or more than $1 billion annually of peak sales.
Leadership believes there are just over 25,000 individuals with RRP just in the U.S. and PAPZIMEOS has reached less than 3% of that target market. FDA approval of PAPZIMEOS validated Precigen’s proprietary AdenoVerse platform. PRGN – 2009 was developed off of this platform. The pipeline asset is in midstage development as part of a combination therapy to treat HPV cancers. Precigen has several other candidates in its pipeline that is in earlier staged development. The company’s balance sheet is in solid shape and should improve as Precigen uses its positive cash to pay down its long-term debt of roughly $95 million.
Currently, the analyst consensus has PGEN earning 24 cents a share in FY2026, follow by over 60 cents a share in FY2027 on over 80% sales growth. That makes PGEN a more than reasonable priced GARP stock in my view.
Option Strategy
This is how one can initiate a holding in PGEN with a covered call order. As a reminder, covered-call orders involve buying an equity and simultaneously selling call strikes against the new position.
Using the July $4 call strikes, fashion a covered call order with a net debit in the $3.00 to $3.20 a share range (net stock price – option premium).
This strategy provides downside protection of just over 25% with upside potential of nearly 30% at the midpoint of the net debit range even if the stock falls 4% from here over the option duration.
At the time of publication, Jensen was long PGEN.
